Lipocine Inc.
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
LPCN | NDAQ
Overview
Corporate Details
- ISIN(s):
- US53630X1046
- LEI:
- Country:
- United States of America
- Address:
- 675 ARAPEEN DRIVE, SUITE 202, 84108 SALT LAKE CITY
- Website:
- https://www.lipocine.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders. The company leverages its proprietary Lip'ral® drug delivery technology to improve the oral absorption of water-insoluble drugs, thereby enhancing patient compliance and therapeutic efficacy. Its development pipeline targets conditions such as liver disease (NASH), postpartum depression, obesity, and hypogonadism. Lipocine's portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. The company's strategy often involves repositioning established drugs through the 505(b)(2) regulatory pathway to create innovative products with improved delivery profiles.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Lipocine Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lipocine Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lipocine Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
